【摘要】 目的   观察血管内皮细胞生长因子抑制剂(Ranibizumab)在新生血管性青光眼(NVG)治疗中的作用。 方法    回顾性分析我院治疗的22例(26眼)NVG患者，玻璃体腔注射Ranibizumab，7～20d后行玻璃体切割手术。随诊6个月，观察新生血管、视力、眼压及眼底情况。结果   1例(2眼)失访。21例(24眼)均有效保存了眼球，其中22眼(91.67％)视力提高，2眼(8.33％)视力不变。术后3 d、7 d、1个月、3个月、6个月较术前平均提高1.20、1.85、2.41、4.12和6.05)。患者无局部和全身不良反应。 结论   Ranibizumab可减少虹膜和视网膜新生血管，联合微创玻璃体切割手术是治疗NVG的有效方法，手术时机为Ranibizumab注射后7～20 d。
      【关键词】 血管内皮细胞生长因子抑制剂；新生血管性青光眼；玻璃体切割手术
      【Abstract】 Objective   To investigate the efficacy of ranibizumab on neovascular glaucoma(NVG) therapy． Methods   A total of 22 patients(26 eyes)with NVG，receiving treatment in our hospital，were selected in the retrospectively analyzed in this study．All participants underwent vitrectomy after 7～12 days of intravitreal injection with ranibizumab and followed uD for 6 months to observe neovascularization，visual acuity：intraocular pressure and fundus condition． Results   One patient (2 eyes)was lost to follow up．21 patients (24 eyes) successfully kept saved their eyeballs，including 22 eyes (91.67％) with
improved visual acuity and 2 eyes(8.33％)with unchanged visual acuity．At 3 d，7 d，1 m，3 m and 6 m after operation，the visual acuity increased 1.20，1.85，2.41，4.12 and 6.45 letters by average，respectively．The mean intraocular pressure (10P)was 24.14 mmHg，21.33 mmHg，17.25 mmHg，18.24 mmHg and 18.54 mmHg，respectively．Compared with the level of pre-treatment，the difference was statistically significant(P<0.05)．There was no local and systemic adverse reaction in all patients． Conclusion    Ranibizumab may reduce neovaseularization in iris and retina．Ranibizumab iS an effective treatment for NVG especially combined with minimally invasive vitreoretinal surgery at appropriate time after 7～12 days of intravitreal injection．When in combination with minimally invasive vitreoretinal surgery ranibizumab is effective for NVG．The best operation timing is 7～20 days after injection．
      【Key words】 Ranibizumab；Neovascular glaucoma (NVG)；Vitrectomy